NSAIDs Used Despite Contraindications
Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability.
Search for Terms or Answers
Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability.
University of Virginia School of Medicine researchers have identified a potential treatment for the respiratory symptoms of long COVID after discovering an unknown cause of the condition inside the lungs.
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?
A secondary analysis of the PEXIVAS study showed antineutrophil cytoplasmic antibody–associated vasculitis (AAV) patients complicated by diffuse alveolar hemorrhage (DAH) may have improved with plasma exchange and glucocorticoids, the results did not achieve significance.
There are numerous impediments to diagnosis or referral; and a new study evaluates patient use of a mobile artificial intelligence (AI)–based symptom checker for diagnoses, but demonstrated only modest accuracy when applied to a cohort of patients with joint symptoms.
One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more effective than others.
A study from the Leiden Early Arthritis Clinic shows that is rheumatoid arthritis (RA) is diagnosed within 12 weeks after symptom onset, treatment costs were lower in both autoantibody-negative and autoantibody-positive RA.
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.